10x Genomics, Inc. (TXG) Q3 2024 Earnings Call Transcript
10x Genomics, Inc. (NASDAQ:TXG ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Cassie Corneau - Senior Director, Head of Investor Relations and Strategic Finance Serge Saxonov - Chief Executive Officer and Co-Founder Adam Taich - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Tycho Peterson - Jefferies Doug Schenkel - Wolfe Research Dan Arias - Stifel Nicolaus Dan Brennan - TD Cowen Mason Carrico - Stephens Puneet Souda - Leerink Partners Rachel Vatnsdal - J.P. Morgan Kyle Mikson - Canaccord Genuity Patrick Donnelly - Citi Michael Ryskin - Bank of America Subbu Nambi - Guggenheim Securities Matt Larew - William Blair Matt Sykes - Goldman Sachs Operator Thank you for standing by.
10x Genomics (TXG) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
10x Genomics (TXG) Reports Q3 Loss, Tops Revenue Estimates
10x Genomics (TXG) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.51 per share a year ago.
Lower Instruments Sales to Hurt TXG Q3 Earnings, Prelim Sales Down
Per a preliminary report from 10x Genomics, the company's revenues will decline for the third quarter. Lower Instruments sales are likely to have been partially offset by consumable sales growth.
10x Genomics (TXG) Upgraded to Strong Buy: Here's Why
10x Genomics (TXG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
10x Genomics (TXG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10x Genomics: Deciphering The Preliminary Q3 Earnings
10x Genomics has faced significant revenue declines and operational challenges, with Q3 revenue missing expectations and instrument sales dropping 46% year-over-year. Despite the setbacks, consumables and services revenue showed growth, indicating customer retention and continued use of 10x's platforms. The company is undergoing commercial process adjustments and remains confident in its long-term growth prospects, despite current economic pressures and competition.
10x Genomics Crashes After 'Disruptive' Reorg Upsets Third-Quarter Sales
10x Genomics stock crashed Thursday after the medtech reported preliminary third-quarter sales that widely missed Street expectations.
10x Genomics, Inc. (TXG) Q2 2024 Earnings Call Transcript
10x Genomics, Inc. (NASDAQ:TXG ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Cassie Corneau - Director-Investor Relations & Strategic Finance Serge Saxonov - Chief Executive Officer and Co-Founder Justin McAnear - Chief Financial Officer Conference Call Participants Daniel Arias - Stifel Tejas Savant - Morgan Stanley Madeline Mollman - Wolfe Research Marta Zaremba - JPMorgan Kyle Boucher - TD Cowen Kyle Mikson - Canaccord Genuity Michael Ryskin - Bank of America Matthew Sykes - Goldman Sachs Matt Larew - William Blair Luke Sergott - Barclays Operator Thank you for standing by. My name is Kayla and I will be your conference operator today.
10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
10x Genomics (TXG) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.53 per share a year ago.
Unlocking Q2 Potential of 10x Genomics (TXG): Exploring Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for 10x Genomics (TXG), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
